GU Cancers 2021 | Immunotherapeutic targets and therapy for RCC
Giuseppe Procopio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, gives an overview of the rapidly evolving treatment landscape for renal cell carcinoma (RCC), highlighting immunotherapeutic targets and therapies. Dr Procopio outlines the potential to improve response rates, progression-free survival (PFS) and overall survival (OS) for patients with RCC by using immunotherapies. Dr Procopio also discusses the combination of immunotherapies such as nivolumab plus ipilimumab, and the combination of immunotherapies with multikinase inhibitors, such as nivolumab plus cabozantinib, or with PD1 inhibitors such as pembrolizumab plus axitinib. Finally, Dr Procopio discusses the challenges of choosing the optimal immunotherapy regimen for each patient. This interview took place during the 2021 Genitourinary Cancers Symposium.
Disclosures
Dr Giuseppe Procopio, MD, has participated in an advisory role for AstraZeneca, Bayer, Ipsen, Janssen, Merckx, MSD Pharmaceuticals, Novartis, Pfizer and BMS.
